Dr. Askari testifies before Congress on drug pricing
The U.S. Senate’s Special Committee on Aging has asked Fred Askari, M.D., Ph.D., to provide testimony today at 3:30 p.m. as lawmakers examine the business practices of Valeant Pharmaceuticals.
Valeant has faced scrutiny for price increases on drugs such as Cuprimine used by patients to treat Wilson disease, an inherited liver disorder. Askari, an associate professor of hepatology at the University of Michigan Health System who specializes in treating Wilson disease, is expected to describe the impact of higher drug prices.
The hearing, “Valeant Pharmaceuticals’ Business Model: the Repercussions for Patients and the Health Care System,” will include testimony from company leaders.
Valeant is known to spend less on research and development compared to other drug companies and has grown through acquisitions and an aggressive pricing strategy. A House Committee has asked Valeant for more information about a big price increase on two of its heart drugs.
Dr. Askari will provide a 5-minute statement during his testimony and then answer questions from committee members. Click here to watch.